Anterior|Siguiente

Análisis de la eficacia de la sustitución de la cabra por la gacela en la píldora antihipertensiva compuesta de Martindale para la hipertensión arterial espontánea en ratas

  • role： First author第一作者
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

  • Email：18767687242@163.com
  • Introduction：王藤剑，在读硕士，从事中药及其复方活性成分发现及靶点互作机制研究，E-mail：18767687242@163.com
WANG Tengjian,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

ZHAO Wanlu,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

YU Yang,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

LIU Yan,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

CAO Kun,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

LIN Zheyuan,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

WU Yue,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

LUO Lilan,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

LAI Weizhi,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

LOU Zhaohuan,  
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

ZHANG Qiaoyan,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

  • Email：zql20161065@zcmu.edu.cn
  • Introduction：张泉龙，博士，副教授，硕士生导师，从事中药及其复方活性成分发现及靶点互作机制研究，E-mail：zql20161065@zcmu.edu.cn； *
ZHANG Quanlong*,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Pharmaceutical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053， China

  • Email：lpqin@zcmu.edu.cn
  • Introduction：秦路平，博士，教授，博士/硕士生导师，从事中药资源及品质评价研究，E-mail：lpqin@zcmu.edu.cn
QIN Luping*

resumen

Objetivo: En el marco de la reducción de la presión arterial, el estudio trata sobre la proporción óptima de la cabra en reemplazo de la gacela en la píldora antihipertensiva compuesta de Martindale, y su mecanismo de acción hipotensor. Método: En los experimentos sobre el efecto antihiperten...D A término de 4 semanas de administración, la presión arterial de las ratas se midió antes de la administración, 3 horas después y cada 2 semanas. Al examinar el efecto antihipertensivo de los huesos de cabra en reemplazo de los huesos de gacela en la fórmula compuesta, 48 ratas espontáneamente hipertenion de la enzima convertidora de angiotensina (ACE), angiotensina II (Ang II), renina (Renina), interleucina 6 (IL-6); la tinción con hematoxilina-eosina (HE) fue examinada en corazón, riñón y aorta torácica. Los niveles de ACE2, receptor de angiotensina II tipo 1 (AT1R), angiotensinaógeno (AGT), en loscada de los ratones con grupo de huesos de cabra 6 veces.

palabra clave

Hueso de cabra; hueso de gacela; píldora antihipertensiva Martindale; hipertensión arterial

References

  1. 1.
    MA L Y，WANG Z W，FAN J，et al.Epidemiology and management of hypertension in China： An analysis using data from the Annual Report on Cardiovascular Health and Diseases in China（2021）［J］.Chin General Pract，2022，25（30）：3715-3720.
  2. 2.
    ZHANG M，SHI Y，ZHOU B，et al.Prevalence，awareness，treatment，and control of hypertension in China，2004-18：findings from six rounds of a national survey［J］.BMJ，2023，380：e071952.
  3. 3.
    QIAO L J，LI B，WANG Y X，et al.Evidence mapping of clinical research on prevention and treatment of essential hypertension with Chinese patent medicines in recent six years［J］.China J Chin Mater Med，2022，47（19）：5375-5382.
  4. 4.
    WANG Y C，ZHANG Y M，XU X D，et al.Gouteng prescription treats primary hypertension with anxiety disorder in patients with syndrome of Yang hyperactivity and heat toxin：Clinical efficacy and impact on balance of inflammatory cytokines［J］.Chin J Exp Tradit Med Form，2023，29（24）：138-145
  5. 5.
    LUAN H Q.Clinical research progress of traditional Chinese medicine in the treatment of hypertensive cerebral hemorrhage［J］.Guangming J Chin Med，2016，31（18）：2751-2753.
  6. 6.
    ZHANG Y H，QIN Y，SHAO G.Effect of Huatan Tongluo prescription on vulnerability of carotid atherosclerotic plaque in hypertension［J］.Chin J Exp Tradit Med Form，2023，29（19）：151-159.
  7. 7.
    LIU H.Research progress on identification of antelope horn medicinal materials［J］.Guangming J Chin Med，2022，37（16）：3060-3062.
  8. 8.
    ZHAO X W，SONG F B，MAO K C.Clinical application of antelope horn［J］.Capital Food Med，2019，26（18）：190-191.
  9. 9.
    YUE C M，XIAO Y L，LONG X H，et al.Tongren Niuhuang Qingxin pills in treating hypertensive vertigo of phlegm-heat invading upward type［J］.Chin Med Mod Distance Edu China，2024，22（1）：76-79.
  10. 10.
    FANG X J，QIAN B Q.Impact of saiga horn capsule on blood pressure variability，pulse pressure and left ventricular mass in elderly patients with isolated systolic hypertension［J］.China J Tradit Chin Med Pharm，2010，25（6）：936-938.
  11. 11.
    MENG Z B.Explanations on the CITES and the domestic policies in relation to saiga （Saiga tatarica）［J］.Mod Chin Med，2011，13（7）：3-5.
  12. 12.
    WU W X，LIU R，ZHAO J J，et al.Research progress on medicinal value of goat horn［J］.Chin Tradit Herbal Drugs，2022，53（9）：2825-2838.
  13. 13.
    LIU R，ZHU Z，QIAN D，et al.Comparison of the peptidome released from keratins in Saiga antelope horn and goat horn under simulated gastrointestinal digestion［J］.Electrophoresis，2019，40（20）：2759-2766.
  14. 14.
    CHEN F R，SHANG D D，JIANG X，et al.Experimental study on horns of Capra hircus instead of horns of Saiga tataria［J］.Drug Evaluation Res，2015，38（1）：49-52.
  15. 15.
    JIANG Q H，ZHAI Y J.Pharmacological action comparison between Cornu antelopis and Cornu caprae hircus［J］.Shanxi Med J，2006，34（7）：582-583.
  16. 16.
    LI P F，LI Y Q，MA Q T，et al.Experimental study on pharmacodynamics of Lingyang Qingfei granule（endangered substitute）［J］.Guiding J Tradit Chin Med Pharm，2020，26（4）：24-29.
  17. 17.
    SI Y P.Using the classical theory of traditional Chinese medicine dialectical treatment of hypertension［J］.Inner Mongolia J Tradit Chin Med，2019，38（5）：79-80.
  18. 18.
    ZHAO Q，WEI H.Pharmacology and traditional Chinese medicine pharmacology experimental guidance［M］.Xi'an： Shanxi Science and Technology Press，2014.
  19. 19.
    LV G Y，CHEN S H，CHEN N，et al.The effects of Lingjiaojiangyafang and its disassembled on the symptoms of ganyangshangkang hypertension［J］.Chin Pharmacol Bull，2010，26（11）：1532-1534.
  20. 20.
    YAO X D，LU Y Z，ZHU C H，et al.Clinical observation on treatment of 50 cases of hypertension with hyperactivity of liver-Yang by antelope horn decoction combined with valsartan amlodipine tablet［J］.Cardiovascul Dis Electronic J Integr Tradit Chin Western Med，2016，4（20）：168-169.
  21. 21.
    WANG M，ZHOU X J.Research progress of traditional Chinese medicine treatment of resistant hypertension［J］.Asia-Pacific Tradit Med，2024，20（2）：245-250.
  22. 22.
    TE RIET L，VAN ESCH J H，ROKS A J，et al.Hypertension： renin-angiotensin-aldosterone system alterations［J］.Circ Res，2015，116（6）：960-975.
  23. 23.
    MENNUNI S，RUBATTU S，PIERELLI G，et al.Hypertension and kidneys： Unraveling complex molecular mechanisms underlying hypertensive renal damage［J］.J Hum Hypertens，2014，28（2）：74-79.
  24. 24.
    SOUTH A M，SHALTOUT H A，WASHBURN L K，et al.Fetal programming and the angiotensin-（1-7） axis：A review of the experimental and clinical data［J］.Clin Sci （Lond），2019，133（1）：55-74.
  25. 25.
    ZHANG Y Y，JIN P P，BIAN D，et al.Mechanism of modified Zhenwutang in delaying renal interstitial fibrosis in chronic renal failure based on Ang Ⅱ/AT1R/NOX4 signaling pathway［J］.Chin J Exp Tradit Med Form，2023，29（16）：89-99.
  26. 26.
    PAN X，SHAO Y，WU F，et al.FGF21 prevents angiotensin Ⅱ-induced hypertension and vascular dysfunction by activation of ACE2/Angiotensin-（1-7） axis in mice［J］.Cell Metab，2018，27（6）：1323-1337.
  27. 27.
    HU J Y，ZHU Y，LIU J F，et al.Study on the antihypertensive effect of compound Gaoziban tablet on spontaneous hypertension rats and the regulation mechanism of RAAS［J］.World Sci Technol Mod Tradit Chin Med，2021，23（7）：2227-2236.
  28. 28.
    AGITA A，ALSAGAFF M T.Inflammation， immunity， and hypertension［J］.Acta Med Indones，2017，49（2）：158-165.
  29. 29.
    ZHANG Z，ZHAO L，ZHOU X，et al.Role of inflammation， immunity，and oxidative stress in hypertension：New insights and potential therapeutic targets［J］.Front Immunol，2023，13：1098725.
  30. 30.
    BIANCARDI V C，BOMFIM G F，REIS W L，et al.The interplay between angiotensin Ⅱ，TLR4 and hypertension［J］.Pharmacol Res，2017，120：88-96.
  31. 31.
    DANGE R B， AGARWAL D，MASSON G S，et al.Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin Ⅱ-induced hypertension［J］.Cardiovasc Res，2014，103（1）：17-27.
  32. 32.
    TAN S，XU M，KE B，et al.IL-6-driven FasL promotes NF-κB p65/PUMA-mediated apoptosis in portal hypertensive gastropathy［J］.Cell Death Dis，2019，10（10）：748.
  33. 33.
    LIN Y M，BADREALAM K F，KUO W W，et al.Nerolidol improves cardiac function in spontaneously hypertensive rats by inhibiting cardiac inflammation and remodelling associated TLR4/NF-κB signalling cascade［J］.Food Chem Toxicol，2021，147：111837.
  34. 34.
    LI Y T，LEI Z Q，YOU Y，et al.Mechanism of Buyang Huanwutang in regulating macrophage cell polarization based on TLR4/NF-κB/NLRP3 Pathway［J］.Chin J Exp Tradit Med Form，2023，29（19）：18-25.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website